ClinicalTrials.gg
Active, not recruitingNCT03312465Updated Aug 25, 2026

Anatomical Shoulder Domelock System Study

An observational study in Avascular Necrosis, Revision Surgery and Conditions Consequent to Earlier Operations, sponsored by Zimmer Biomet. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Zimmer Biomet · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
73
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 57 studies in Osteonecrosis by Zimmer Biomet — 3 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · Zimmer Biomet.

Enrollment
28th of 41
73 · median 118
Started
2017
with 3 others
Observational
41 of 57
1 open now
Primary completion
2032-12
later than 10 of 14 live
Registered
34th of 57
by date

Among the 57 studies in Osteonecrosis by Zimmer Biomet, this one is the 28th largest by enrollment of the 41 observational ones that give a count, is one of 4 that started in 2017, is one of 41 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 34th registered.

Osteonecrosis

287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.

Browse Osteonecrosis studies →

Open to participants now

3 of the 57 studies in Osteonecrosis by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteonecrosis by Zimmer Biomet, or all of them as a file.
02

Study summary

The objectives of this study are to confirm safety and performance of the Anatomical Shoulder Domelock System when used in hemi or total shoulder arthroplasty by analysis of standard scoring systems, radiographs and adverse event records.

Read the detailed description

This study is a multicenter, prospective and retrospective, non-controlled PMCF study involving orthopaedic surgeons skilled in hemi and total shoulder arthroplasty procedures. A minimum of six study centers will be involved and a total number of 73 implants will be included into the study.

03

Conditions studied

  • Avascular Necrosis
  • Revision Surgery
  • Conditions Consequent to Earlier Operations
  • Arthritis, Rheumatoid
  • Arthritis, Degenerative
  • Arthritis;Traumatic

Keywords

  • Total Shoulder Arthroplasty
  • Hemi Shoulder Arthroplasty
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients suffering from severe shoulder pain and disability indicated for implantation of the Anatomical Shoulder Domelock System in hemi or total shoulder arthroplasty and who meet all inclusion and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18-80 years of age, inclusive
  • Patient is skeletally mature
  • Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history
  • Patient has failed conservative treatment
  • Patient meets at least one of the following indications:

    • Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis if bone stock is adequate.
    • Avascular necrosis
    • Conditions consequent to earlier operations
    • Optional use in revision: in some medical conditions (e.g., early revision when adequate bone stock exists), the surgeon may opt to use primary implants in a revision procedure.

Additional criteria for retrospective patients:

  • patient has been implanted with the Domelock system before site initiation visit.
  • information available must include at minimum demographic information, the operative report and details of the device implanted.

Exclusion criteria

Exclusion Criteria:

  • Patient is unwilling or unable to give consent or to comply with the follow-up program
  • Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them
  • Patient is known to be pregnant or breastfeeding
  • Patient meets at least one of the :

    • Patient's physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant, e.g., previous surgery, insufficient quality or quantity of bone, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention e.g., absence of musculoligamentous supporting structures, joint neuropathy or other conditions that may lead to inadequate skeletal fixation
    • Signs of infection
    • Severe instability secondary to advanced loss of osteochondral structure
    • Charcot's shoulder (neuroarthropathy)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
73 participants (actual)
Patient registry
No

Groups and cohorts

  • AS Domelock System Subjects

    Subjects that receive the Anatomical Shoulder Domelock System

    Device: AS Domelock System

Interventions

  • DeviceAS Domelock System

    Hemi or Total Shoulder Arthroplasty

06

What researchers measure

Primary outcomes

  1. Implant Survivorship

    The primary endpoint of this study is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method.

    Time frame: 10 Years

Secondary outcomes

  1. Clinical Performance

    The secondary endpoint is defined by the performance of the Anatomical Shoulder Domelock System at 5 years, which is assessed by the Constant and Murley score. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points.

    Time frame: 5 Years

07

Study locations

6 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2032, 182 months after the start.

Of 59 observational studies under Osteonecrosis, half reached primary completion within 141 months of starting (the median), counting those still running; a quarter within 93 and three quarters within 184. This study's planned 182 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Oct 17, 2017
StartActual
Sep 28, 2017
Primary completionEst.
Dec 9, 2032
CompletionEst.
Dec 9, 2032
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03312465
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Oct 17, 2017
Start date
Sep 28, 2017
Primary completion
Dec 9, 2032 (estimated)
Completion
Dec 9, 2032 (estimated)
Last update
Aug 25, 2026

Study contacts

Emilie Rohmer
study director · Zimmer Biomet Clinical Operations

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion